Vasilios G. Athyros

List of Publications by Citations

304 papers	10,039 citations	53 h-index	88 g-index
387 ext. papers	11,490 ext. citations	3.8 avg, IF	6.04 L-index

#	Paper	IF	Citations
304	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet, The*, **2010**, 376, 1916-22	40	459
303	Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2692-701	5.6	445
302	Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. *Current Medical Research and Opinion*, **2002**, 18, 220-8	2.5	424
301	The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. *Journal of Clinical Pathology*, **2004**, 57, 728-34	3.9	261
300	Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. *Diabetes Care*, **2002**, 25, 1198-202	14.6	226
299	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. *Metabolism: Clinical and Experimental*, **2006**, 55, 1293-301	12.7	208
298	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. *Current Medical Research and Opinion*, **2006**, 22, 873-83	2.5	191
297	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. *American Journal of Kidney Diseases*, **2004**, 43, 589-99	7.4	188
296	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. *Nutrition Reviews*, **2017**, 75, 307-326	6.4	183
295	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. *Metabolism: Clinical and Experimental*, **2017**, 71, 17-32	12.7	152
294	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. *Current Vascular Pharmacology*, **2011**, 9, 533-71	3.3	138
293	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. *Current Medical Research and Opinion*, **2005**, 21, 1157-9	2.5	138
292	Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. *American Journal of Cardiology*, **1997**, 80, 608-13	3	132
291	Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. *Journal of Clinical Gastroenterology*, **2002**, 34, 472-5	3	131
290	Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. *Osteoporosis International*, **2009**, 20, 197-207	5.3	117
289	Pleiotropic effects of statins--clinical evidence. *Current Pharmaceutical Design*, **2009**, 15, 479-89	3.3	117
288	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. *Nephrology Dialysis Transplantation*, **2007**, 22, 118-27	4.3	114

287	The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. *Diabetes, Obesity and Metabolism*, **2005**, 7, 397-405	6.7	114
286	Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. *Angiology*, **2007**, 58, 689-97	2.1	113
285	Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 140-6	4.5	111
284	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. *Review of Diabetic Studies*, **2015**, 12, 110-8	3.6	106
283	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. *Diabetes, Obesity and Metabolism*, **2011**, 13, 302-12	6.7	104
282	Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. *American Heart Journal*, **2004**, 148, 635-40	4.9	101
281	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. *World Journal of Gastroenterology*, **2015**, 21, 7860-8	5.6	97
280	Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. *Expert Opinion on Pharmacotherapy*, **2008**, 9, 509-15	4	94
279	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. *World Journal of Gastroenterology*, **2015**, 21, 6820-34	5.6	91
278	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. *Current Vascular Pharmacology*, **2011**, 9, 531-2	3.3	91
277	Serum uric acid as an independent predictor of early death after acute stroke. *Circulation Journal*, **2007**, 71, 1120-7	2.9	91
276	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *European Heart Journal*, **2015**, 36, 1536-46	9.5	88
275	Should adipokines be considered in the choice of the treatment of obesity-related health problems?. *Current Drug Targets*, **2010**, 11, 122-35	3	86
274	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. *Atherosclerosis*, **2007**, 193, 428-37	3.1	82
273	Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. *Atherosclerosis*, **2001**, 157, 463-9	3.1	82
272	Contrast-Induced Nephropathy: An "All or None" Phenomenon?. *Angiology*, **2015**, 66, 508-13	2.1	81
271	Diabetes and lipid metabolism. *Hormones*, **2018**, 17, 61-67	3.1	81
270	Pheochromocytoma: an update on genetics and management. *Endocrine-Related Cancer*, **2007**, 14, 935-56	3.7	81

269	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. *Current Medical Research and Opinion*, **2010**, 26, 713-9	2.5	78
268	Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. *Angiology*, **2003**, 54, 679-90	2.1	77
267	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. *Current Medical Research and Opinion*, **2004**, 20, 1691-1701	2.5	72
266	Prevalence of vascular disease in metabolic syndrome using three proposed definitions. *International Journal of Cardiology*, **2007**, 117, 204-10	3.2	68
265	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. *Metabolism: Clinical and Experimental*, **2013**, 62, 21-33	12.7	66
264	Cardiovascular benefits of bariatric surgery in morbidly obese patients. *Obesity Reviews*, **2011**, 12, 515-24	10.6	66
263	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. *Journal of the American Society of Hypertension*, **2014**, 8, 74-82		64
262	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. *Atherosclerosis*, **2008**, 200, 1-12	3.1	63
261	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. *Current Medical Research and Opinion*, **2004**, 20, 627-37	2.5	62
260	Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. *Current Medical Research and Opinion*, **2003**, 19, 22-7	2.5	60
259	Hyperuricaemia: more than just a cause of gout?. *Journal of Cardiovascular Medicine*, **2013**, 14, 397-402	1.9	58
258	Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. *American Journal of Cardiology*, **2008**, 101, 483-5	3	57
257	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. *Journal of Human Hypertension*, **2004**, 18, 781-8	2.6	57
256	Statins and renal function in patients with diabetes mellitus. *Current Medical Research and Opinion*, **2003**, 19, 615-7	2.5	57
255	Targeting vascular risk in patients with metabolic syndrome but without diabetes. *Metabolism: Clinical and Experimental*, **2005**, 54, 1065-74	12.7	56
254	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 213-21	4.5	55
253	Dyslipidemia as a risk factor for ischemic stroke. *Current Topics in Medicinal Chemistry*, **2009**, 9, 1291-7	3	55
252	Adrenal incidentaloma: a diagnostic challenge. *Hormones*, **2009**, 8, 163-84	3.1	52

251	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. *Archives of Medical Science*, **2011**, 7, 796-805	2.9	51
250	The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. *Current Medical Research and Opinion*, **2004**, 20, 1393-401	2.5	51
249	Uric acid levels and vascular disease. *Current Medical Research and Opinion*, **2004**, 20, 951-4	2.5	51
248	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. *Current Vascular Pharmacology*, **2018**, 16, 246-253	3.3	49
247	Nonalcoholic fatty liver disease and statins. *Metabolism: Clinical and Experimental*, **2015**, 64, 1215-23	12.7	47
246	Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. *Coronary Artery Disease*, **1996**, 7, 843-50	1.4	46
245	Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. *American Journal of Cardiology*, **1996**, 77, 242-6	3	46
244	Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. *Open Cardiovascular Medicine Journal*, **2011**, 5, 24-34	0.7	44
243	Lipoprotein a: where are we now?. *Current Opinion in Cardiology*, **2009**, 24, 351-7	2.1	44
242	Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. *Current Vascular Pharmacology*, **2011**, 9, 698-705	3.3	43
241	Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. *Current Vascular Pharmacology*, **2012**, 10, 162-72	3.3	42
240	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. *International Journal of Nanomedicine*, **2006**, 1, 129-47	7.3	42
239	Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?. *Current Vascular Pharmacology*, **2010**, 8, 720-30	3.3	41
238	Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. *Current Drug Targets*, **2007**, 8, 942-51	3	38
237	Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. *Diabetes Care*, **2003**, 26, 1955-60	14.6	38
236	Dyslipidaemia, hypercoagulability and the metabolic syndrome. *Current Vascular Pharmacology*, **2006**, 4, 175-83	3.3	37
235	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. *Current Medical Research and Opinion*, **2011**, 27, 1659-68	2.5	36
234	Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. *Current Vascular Pharmacology*, **2014**, 12, 627-41	3.3	36

233	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. *Current Vascular Pharmacology*, **2018**, 16, 130-142	3.3	36
232	Role of antihypertensive drugs in arterial de-stiffening and central pulsatile hemodynamics. *American Journal of Cardiovascular Drugs*, **2012**, 12, 143-56	4	35
231	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. *Archives of Medical Science*, **2011**, 7, 984-92	2.9	35
230	The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. *Journal of Clinical Pharmacology*, **2007**, 47, 642-52	2.9	35
229	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1449-61	4	33
228	Statins and solid organ transplantation. *Current Pharmaceutical Design*, **2006**, 12, 4771-83	3.3	33
227	Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. *Journal of Diabetes and Its Complications*, **2006**, 20, 1-7	3.2	31
226	Definitions of metabolic syndrome: Where are we now?. *Current Vascular Pharmacology*, **2006**, 4, 185-97	3.3	31
225	Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. *Angiology*, **2006**, 57, 303-11	2.1	31
224	The role of statins in the treatment of type 2 diabetes mellitus: an update. *Current Pharmaceutical Design*, **2014**, 20, 3665-74	3.3	31
223	Ezetimibe therapy for dyslipidemia: an update. *Current Pharmaceutical Design*, **2013**, 19, 3107-14	3.3	31
222	Atorvastatin: safety and tolerability. *Expert Opinion on Drug Safety*, **2010**, 9, 667-74	4.1	30
221	Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. *Current Vascular Pharmacology*, **2011**, 9, 647-57	3.3	29
220	Atherogenesis in renal patients: a model of vascular disease?. *Current Vascular Pharmacology*, **2008**, 6, 93-107	3.3	29
219	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. *Archives of Medical Science*, **2013**, 9, 418-26	2.9	28
218	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. *International Journal of Clinical Practice*, **2011**, 65, 679-83	2.9	28
217	Fish oils and vascular disease prevention: an update. *Current Medicinal Chemistry*, **2007**, 14, 2622-8	4.3	28
216	High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?. *Current Medicinal Chemistry*, **2014**, 21, 2917-26	4.3	28

215	Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data. *Angiology*, **2014**, 65, 543-50	2.1	27
214	Endothelial function, arterial stiffness and lipid lowering drugs. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 1143-60	6.4	27
213	. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2002**, 9, 33-39		27
212	Should we expand the concept of coronary heart disease equivalents?. *Current Opinion in Cardiology*, **2014**, 29, 389-95	2.1	26
211	Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. *Lipids*, **2007**, 42, 999-1009	1.6	26
210	The natural history of recently diagnosed autonomic neuropathy over a period of 2 years. *Diabetes Research and Clinical Practice*, **1998**, 42, 55-63	7.4	25
209	Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. *International Journal of Clinical Practice*, **2007**, 61, 545-51	2.9	25
208	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. *Current Vascular Pharmacology*, **2020**, 18, 172-181	3.3	24
207	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney International*, **2004**, 66, 1714-5	9.9	24
206	Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. *Current Vascular Pharmacology*, **2014**, 12, 505-11	3.3	24
205	Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. *International Journal of Cardiology*, **2009**, 134, 322-9	3.2	23
204	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. *Current Drug Targets*, **2009**, 10, 320-7	3	23
203	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. *Current Drug Targets*, **2007**, 8, 483-8	3	23
202	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. *Platelets*, **2005**, 16, 65-71	3.6	23
201	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. *Neurological Research*, **2010**, 32, 326-31	2.7	22
200	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. *Open Cardiovascular Medicine Journal*, **2007**, 1, 8-14	0.7	22
199	Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI. *Nature Reviews Nephrology*, **2014**, 10, 8-9	14.9	21
198	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. *Angiology*, **2012**, 63, 358-66	2.1	21

197	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. *Current Opinion in Cardiology*, **2010**, 25, 394-8	2.1	21
196	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. *Current Opinion in Cardiology*, **2010**, 25, 406-10	2.1	21
195	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 191-205	6.4	21
194	Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. *Angiology*, **2014**, 65, 284-93	2.1	20
193	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. *Endocrine-Related Cancer*, **2008**, 15, 693-700	5.7	20
192	Statins for non-alcoholic fatty liver disease: a new indication?. *Alimentary Pharmacology and Therapeutics*, **2006**, 24, 698-9	6.1	20
191	Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction. *American Journal of Cardiology*, **1999**, 84, 1164-9	3	20
190	Anti-inflammatory effects of fibrates: an overview. *Current Medicinal Chemistry*, **2009**, 16, 676-84	4.3	19
189	Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. *Atherosclerosis*, **2002**, 163, 205-6	3.1	19
188	Hyperuricemia as a risk factor for cardiovascular disease. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 19-20	2.5	18
187	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. *Current Medical Research and Opinion*, **2010**, 26, 839-42	2.5	18
186	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. *Current Pharmaceutical Design*, **2018**, 24, 4587-4592	3.3	18
185	The role of statins for the primary and secondary prevention of coronary heart disease in women. *Current Pharmaceutical Design*, **2009**, 15, 1054-62	3.3	17
184	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. *Hellenic Journal of Cardiology*, **2005**, 46, 380-6	2.1	17
183	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. *Maturitas*, **2018**, 108, 45-52	5	16
182	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 723-30	4	16
181	Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. *Current Medical Research and Opinion*, **2009**, 25, 971-80	2.5	16
180	Lipid lowering agents and the endothelium: an update after 4 years. *Current Vascular Pharmacology* , **2012**, 10, 33-41	3.3	16

179	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. *Current Medical Research and Opinion*, **2008**, 24, 1593-9	2.5	16
178	Statin-fibrate combinations in patients with combined hyperlipedemia. *Atherosclerosis*, **2001**, 155, 263-4	3.1	16
177	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. *Journal of Crohn's and Colitis*, **2014**, 8, 936-44	1.5	15
176	Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. *Current Medical Research and Opinion*, **2002**, 18, 499-502	2.5	15
175	The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. *Current Vascular Pharmacology*, **2013**, 11, 779-84	3.3	15
174	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. *Open Cardiovascular Medicine Journal*, **2018**, 12, 29-40	0.7	15
173	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). *Atherosclerosis*, **2018**, 277, 308-313	3.1	15
172	Brain natriuretic peptide and the athlete's heart: a pilot study. *International Journal of Clinical Practice*, **2010**, 64, 511-7	2.9	14
171	Statins and renal function. Is the compound and dose making a difference?. *Nephrology Dialysis Transplantation*, **2007**, 22, 963-4; author reply 964	4.3	14
170	Colesevelam: a new and improved bile acid sequestrant?. *Current Pharmaceutical Design*, **2013**, 19, 3115-23	3.3	14
169	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. *Open Cardiovascular Medicine Journal*, **2014**, 8, 55-60	0.7	14
168	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. *Current Medical Research and Opinion*, **2016**, 32, 1513-4	2.5	13
167	Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. *Nature Reviews Cardiology*, **2014**, 11, 72-4	14.8	13
166	Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. *Angiology*, **2010**, 61, 49-57	2.1	13
165	Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. *Journal of Diabetes and Its Complications*, **1998**, 12, 201-7	2.2	13
164	Omega-3 fatty acids: how can they be used in secondary prevention?. *Current Atherosclerosis Reports*, **2008**, 10, 510-7	6	13
163	Lipid-lowering therapy in patients with peripheral arterial disease. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2005**, 10, 145-7	2.6	13
162	Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2002**, 9, 33-9		13

161	Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia. *Drug Investigation*, **1994**, 7, 134-142		13
160	Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment. *Current Vascular Pharmacology*, **2015**, 13, 788-800	3.3	13
159	Statins for the prevention of first or recurrent stroke. *Current Vascular Pharmacology*, **2008**, 6, 124-33	3.3	13
158	Implementation of guidelines for the management of arterial hypertension. The impulsion study. *Open Cardiovascular Medicine Journal*, **2009**, 3, 26-34	0.7	13
157	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. *Journal of Diabetes and Its Complications*, **2015**, 29, 142-5	3.2	12
156	Lipid-lowering treatment in peripheral artery disease. *Current Opinion in Pharmacology*, **2018**, 39, 19-26	5.1	12
155	Myocardial perfusion scintigraphy in asymptomatic diabetic patients: a critical review. *Diabetes/Metabolism Research and Reviews*, **2010**, 26, 336-47	7.5	12
154	Statin Treatment May be Beneficial to Both the Kidneys and the Heart. *Peritoneal Dialysis International*, **2007**, 27, 215-216	2.8	12
153	Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. *Journal of Investigative Medicine*, **2005**, 53, 116-22	2.9	12
152	Inflammatory markers and the metabolic syndrome. *Atherosclerosis*, **2005**, 183, 187-8	3.1	12
151	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. *Current Medical Research and Opinion*, **2004**, 20, 1385-92	2.5	12
150	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. *Clinical Drug Investigation*, **1998**, 16, 219-27	3.2	12
149	Dysmetabolic Iron Overload in Metabolic Syndrome. *Current Pharmaceutical Design*, **2020**, 26, 1019-1024	3.3	12
148	Endocrine hypertension: diagnosis and management of a complex clinical entity. *Current Vascular Pharmacology*, **2010**, 8, 646-60	3.3	12
147	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. *Nature Clinical Practice Endocrinology and Metabolism*, **2009**, 5, 16-7		11
146	Should raising high-density lipoprotein cholesterol be a matter of debate?. *Journal of Cardiovascular Medicine*, **2012**, 13, 254-9	1.9	11
145	The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. *Current Vascular Pharmacology*, **2010**, 8, 792-803	3.3	11
144	Intravenous immunoglobulins: a valuable asset in the treatment of a case of septic febrile ulceronecrotic Mucha-Habermann disease. *Dermatology*, **2007**, 215, 164-5	4.4	11

143	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. *Current Pharmaceutical Design*, **2018**, 24, 1879-1886	3.3	11
142	Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. *Current Vascular Pharmacology*, **2016**, 14, 523-533	3.3	11
141	Semaglutide, lipid-lowering drugs, and NAFLD. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 329-330	18.1	10
140	The potential role of statins in treating liver disease. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 331-339	4.2	10
139	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 809-20	6.4	10
138	High density lipoprotein cholesterol and statin trials. *Current Medicinal Chemistry*, **2008**, 15, 2265-70	4.3	10
137	The effect of cholesterol-lowering treatment on renal function. *American Journal of Kidney Diseases* , **2006**, 47, 561; author reply 562	7.4	10
136	Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. *Current Pharmaceutical Design*, **2007**, 13, 229-39	3.3	10
135	A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. *Current Medical Research and Opinion*, **2007**, 23, 1945-56	2.5	10
134	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. *Current Vascular Pharmacology*, **2018**, 16, 214-218	3.3	10
133	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. *Endocrine*, **2020**, 69, 249-261	4	9
132	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 362-3	18.1	9
131	The effect of SGLT2 inhibitors on cardiovascular events and renal function. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1251-1261	3.8	9
130	Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. *Archives of Medical Science*, **2011**, 7, 1067-75	2.9	9
129	Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis. *Metabolic Syndrome and Related Disorders*, **2010**, 8, 523-9	2.6	9
128	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. *Current Medical Research and Opinion*, **2009**, 25, 1931-40	2.5	9
127	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 2267-77	4	9
126	Effects of various fibrates on serum alkaline phosphatase activity. *Atherosclerosis*, **2002**, 165, 187-8	3.1	9

125	Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?. *Current Vascular Pharmacology*, **2018**, 16, 269-275	3.3	9
124	Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. *Current Pharmaceutical Design*, **2010**, 16, 3939-847	3.3	8
123	Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. *QJM - Monthly Journal of the Association of Physicians*, **2005**, 98, 913-5	2.7	8
122	Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. *Nephrology Dialysis Transplantation*, **2007**, 22, 293	4.3	8
121	Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. *Clinical Drug Investigation*, **1998**, 15, 111-21	3.2	8
120	Management of statin-intolerant high-risk patients. *Current Vascular Pharmacology*, **2010**, 8, 632-7	3.3	8
119	Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. *Current Vascular Pharmacology*, **2015**, 13, 368-80	3.3	8
118	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. *Current Vascular Pharmacology*, **2018**, 16, 254-268	3.3	8
117	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. *Angiology*, **2022**, 73, 87	2.1	8
116	Statins and non-alcoholic steatohepatitis. *Journal of Hepatology*, **2016**, 64, 241-2	13.4	7
115	Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. *Open Cardiovascular Medicine Journal*, **2011**, 5, 85-9	0.7	7
114	Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors. *QJM - Monthly Journal of the Association of Physicians*, **2006**, 99, 197-8	2.7	7
113	Dry cough as first manifestation of giant-cell arteritis. *Journal of the American Geriatrics Society*, **2006**, 54, 1957-8	5.6	7
112	Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. *Atherosclerosis*, **2003**, 168, 397-8	3.1	7
111	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. *Current Vascular Pharmacology*, **2018**, 16, 393-400	3.3	7
110	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. *Current Pharmaceutical Design*, **2018**, 24, 3638-3646	3.3	7
109	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). *Hormones*, **2017**, 16, 306-312	3.1	6
108	Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*, **2016**, 22, 2206-12	4.5	6

107	Beliefs and attitudes regarding cardiovascular disease risk factors: a health survey in 10,141 Greek men and women (2006-2012). *International Journal of Cardiology*, **2013**, 168, 4847-9	3.2	6
106	Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. *Current Vascular Pharmacology*, **2016**, 14, 88-97	3.3	6
105	Subclinical Cushing's syndrome and cardiovascular disease. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 361	18.1	6
104	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. *Digestive Diseases and Sciences*, **2012**, 57, 1109	4	6
103	Statins in patients with renal dysfunction. *American Journal of Cardiology*, **2012**, 109, 1537	3	6
102	Statins and heart failure. *Journal of the American College of Cardiology*, **2010**, 55, 1644-5; author reply 1646	15.1	6
101	Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. *Angiology*, **2009**, 60, 74-81	2.1	6
100	Statins and regression of coronary atherosclerosis. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2197; author reply 2197	27.4	6
99	Undertreatment of dyslipidaemia in Greece. *Atherosclerosis*, **2004**, 177, 215-6	3.1	6
98	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. *Current Vascular Pharmacology*, **2021**, 19, 572-581	3.3	6
97	Treatment strategies for hypertension in patients with type 1 diabetes. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1241-1252	4	5
96	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. *Journal of Clinical Hypertension*, **2018**, 20, 942-948	2.3	5
95	Statins and non-alcoholic steatohepatitis. *Metabolism: Clinical and Experimental*, **2017**, 66, e1-e2	12.7	5
94	Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure. *Current Pharmaceutical Design*, **2014**, 20, 6306-13	3.3	5
93	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. *Current Pharmaceutical Design*, **2017**, 23, 1477-1483	3.3	5
92	Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters. *Open Cardiovascular Medicine Journal*, **2012**, 6, 122-5	0.7	5
91	Antihypertensive therapy in acute ischemic stroke: where do we stand?. *Journal of Human Hypertension*, **2018**, 32, 799-807	2.6	5
90	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 1059-66	2.5	4

89	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. *Current Vascular Pharmacology*, **2019**, 17, 425-428	3.3	4
88	Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. *American Journal of Cardiology*, **2012**, 110, 763	3	4
87	Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. *Journal of Hepatology*, **2012**, 57, 476	13.4	4
86	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. *Journal of Drug Assessment*, **2013**, 2, 67-71	1.5	4
85	Impact of statins on glucose metabolism--a matter of debate. *American Journal of Cardiology*, **2011**, 107, 1866	3	4
84	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. *American Journal of Physiology - Renal Physiology*, **2017**, 312, G681-G682	5.1	3
83	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. *Expert Opinion on Drug Safety*, **2019**, 18, 241-251	4.1	3
82	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. *Diabetes and Vascular Disease Research*, **2015**, 12, 471-2	3.3	3
81	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. *Journal of Clinical Hypertension*, **2018**, 20, 255-257	2.3	3
80	Peripheral artery disease in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2014**, 28, 912	3.2	3
79	The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. *Archives of Medical Science*, **2012**, 8, 6-10	2.9	3
78	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. *Clinical Cardiology*, **2009**, 32, 230	3.3	3
77	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 287-8; author reply 289-90	4	3
76	New-onset diabetes after transplantation. *Lancet, The*, **2005**, 365, 1766	40	3
75	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia -A Pilot Study. *Current Medical Research and Opinion*, **2001**, 17, 267-272	2.5	3
74	Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. *Open Cardiovascular Medicine Journal*, **2011**, 5, 226-30	0.7	3
73	Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. *Open Cardiovascular Medicine Journal*, **2012**, 6, 28-32	0.7	3
72	Homocysteine: An Emerging Cardiovascular Risk Factor that Never Really Made it~!2009-10-29~!2009-12-27~!2010-04-08~!. *The Open Clinical Chemistry Journal*, **2010**, 3, 19-24		3

71	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. *Journal of Clinical Hypertension*, **2016**, 18, 1073	2.3	3
70	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. *Clinical Lipidology*, **2016**, 11, 2-5		3
69	Arterial stiffness correlates with the severity of hepatic fibrosis in patients with nonalcoholic fatty liver disease. *Atherosclerosis*, **2017**, 263, e197	3.1	2
68	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. *Journal of Hypertension*, **2018**, 36, 701	1.9	2
67	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. *Journal of Clinical Hypertension*, **2018**, 20, 634-636	2.3	2
66	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. *Journal of Clinical Hypertension*, **2018**, 20, 469-471	2.3	2
65	Contrast-induced acute kidney injury: beware of the risk after coronary angiography. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 73	2.5	2
64	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. *Hormones*, **2018**, 17, 83-95	3.1	2
63	Statin use in patients with diabetes: one drug, multiple benefits. *Expert Review of Cardiovascular Therapy*, **2019**, 17, 839-840	2.5	2
62	Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. *Current Medical Research and Opinion*, **2014**, 30, 57-8	2.5	2
61	Response to ØMildly decreased glomerular filtration rate is associated with poor coronary heart disease outcomeØ*Clinical Cardiology*, **2012**, 35, 315; author reply 316-7	3.3	2
60	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. *Journal of Clinical Lipidology*, **2013**, 7, 88	4.9	2
59	Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 861-2	6.4	2
58	Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance. *Circulation Journal*, **2011**, 75, 2027; author reply 2028	2.9	2
57	Comment and reply on: Atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link?. *Expert Opinion on Drug Safety*, **2010**, 9, 1005-6; author reply 1006	4.1	2
56	Targeting triglycerides in secondary prevention: should we bother?. *International Journal of Clinical Practice*, **2009**, 63, 15-8	2.9	2
55	Current treatment for nonalcoholic fatty liver disease. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 2141-2; author reply 2142	4	2
54	Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. *American Journal of Cardiology*, **2008**, 101, 1679-80	3	2

53	Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia. *Current Therapeutic Research*, **1994**, 55, 914-924	2.4	2
52	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia - A Pilot Study. *Current Medical Research and Opinion*, **2001**, 17, 267-272	2.5	2
51	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. *Open Cardiovascular Medicine Journal*, **2016**, 10, 64-8	0.7	2
50	Response letter: Statins and non-alcoholic steatohepatitis. *Metabolism: Clinical and Experimental*, **2017**, 66, e6	12.7	1
49	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. *Current Medical Research and Opinion*, **2019**, 35, 1305-1306	2.5	1
48	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. *Journal of Clinical Hypertension*, **2018**, 20, 589-591	2.3	1
47	Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. *American Journal of Cardiology*, **2016**, 117, 311-2	3	1
46	Treating heart failure with preserved ejection fraction: statins could make the difference. *Angiology* , **2014**, 65, 328-9	2.1	1
45	Therapy: Caloric and fat intake in statin users. *Nature Reviews Endocrinology*, **2014**, 10, 450-1	15.2	1
44	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 295-6	2.5	1
43	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. *Journal of Clinical Lipidology*, **2012**, 6, 93	4.9	1
42	Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients. *Current Medical Research and Opinion*, **2013**, 29, 791-2	2.5	1
41	Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. *Circulation Journal*, **2013**, 77, 1348	2.9	1
40	Cold temperature and cardiovascular mortality. *Circulation Journal*, **2013**, 77, 2846	2.9	1
39	Raised liver enzymes in patients taking statins □AuthorsOreply. *Lancet, The*, **2011**, 377, 1075-1076	40	1
38	Does metabolic syndrome influence outcome following percutaneous coronary intervention?. *Angiology*, **2011**, 62, 437-9	2.1	1
37	Additional effects of statins in surgical patients. *Annals of Surgery*, **2008**, 248, 140-1; author reply 141	7.8	1
36	Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia. *Clinical Drug Investigation*, **1996**, 11, 196-204	3.2	1

35	Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. *Oman Medical Journal*, **2012**, 27, 177	1.4	1
34	Adherence to statin treatment: an important issue in clinical practice. *Current Medical Research and Opinion*, **2016**, 32, 1639-1640	2.5	1
33	NAFLD and Statins. *Digestive Diseases and Sciences*, **2020**, 65, 3052-3053	4	1
32	Multifactorial treatment of diabetic patients with cardiovascular disease to maximize results. *Journal of Diabetes and Its Complications*, **2021**, 35, 107904	3.2	1
31	Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. *Expert Review of Cardiovascular Therapy*, **2021**, 19, 575-580	2.5	1
30	Off target effects of statins shape total mortality?. *Journal of Drug Assessment*, **2016**, 5, 4-5	1.5	1
29	Should atenolol still be recommended as first-line therapy for primary hypertension?. *Hellenic Journal of Cardiology*, **2006**, 47, 298-307	2.1	1
28	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. *Atherosclerosis*, **2015**, 238, 182-4	3.1	0
27	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. *Journal of Clinical Hypertension*, **2019**, 21, 1578-1579	2.3	0
26	Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. *Current Pharmaceutical Design*, **2018**, 24, 5542-5547	3.3	0
25	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. *Hormones*, **2021**, 1	3.1	0
24	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr Med Res Opin 2017;33:797-801. *Current Medical Research and Opinion*, **2017**, 33, 2261-2262	2.5	
23	Statins and substantially increased ALT values at baseline. *Cardiovascular Therapeutics*, **2018**, 36, e12444	3.3	
22	Priority Paper Evaluation: Are antibodies against PCSK9 the statins of the 21st century?. *Clinical Lipidology*, **2014**, 9, 141-144		
21	Alcohol consumption and the heart. *International Journal of Cardiology*, **2013**, 168, 4319	3.2	
20	Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol. 2016;10(5):1091-1097. *Journal of Clinical Lipidology*, **2017**, 11, 306-307	4.9	
19	Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention. *Current Medical Research and Opinion*, **2014**, 30, 55	2.5	
18	Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-lowering property". *Digestive and Liver Disease*, **2013**, 45, 82-3	3.3	

17	Management of dyslipidemia in patients with nonalcoholic fatty liver disease **2013**, 98-109	
16	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. *Clinical Lipidology*, **2013**, 8, 509-512	
15	Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review. *Diseases (Basel, Switzerland)*, **2013**, 1, 51-72	4.4
14	Atherosclerotic renal artery stenosis: an update on diagnosis and management. *Current Vascular Pharmacology*, **2011**, 9, 465-70	3.3
13	Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study. *Clinical and Applied Thrombosis/Hemostasis*, **2012**, 18, 113-4	3.3
12	Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult. *Renal Failure*, **2008**, 30, 331-4	2.9
11	Can We Move Forward After ADVANCE?. *Vascular Disease Prevention*, **2008**, 5, 72-74	
10	Vascular Disease and Insulin-Like Growth Factor-1. *Vascular Disease Prevention*, **2007**, 4, 306-313	
9	Long-Term Follow-Up of a Patient with Carcinoid Disease of the Heart. *American Journal of Noninvasive Cardiology*, **1994**, 8, 171-173	
8	Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments. *Current Vascular Pharmacology*, **2021**, 19, 673-674	3.3
7	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. *Open Hypertension Journal*, **2017**, 9, 1-5	0.8
6	Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry. *Atherosclerosis* , **2020**, 315, e39-e40	3.1
5	Effect of high and low dose of rosuvastatin on fatty liver disease and adipokines in patients with nonalcoholic fatty liver disease. *Atherosclerosis*, **2020**, 315, e98-e99	3.1
4	Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. *Atherosclerosis*, **2020**, 315, e210-e211	3.1
3	Ertugliflozin + metformin as a treatment option for type 2 diabetes. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 2105-2111	4
2	Statins, renal function and homocysteine. *Pharmacological Reports*, **2016**, 68, 1093	3.9
1	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Oct 1:101816. doi: 10.1016/j.clinre.2021.101816. Epub ahead of print. PMID:34607067.. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 46, 101842	2.4